Detalles de la búsqueda
1.
RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma.
Ann Hematol
; 102(7): 1773-1787, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-37171597
2.
Burden of hospitalizations and outpatient visits associated with moderate and severe acute graft-versus-host disease in Finland and Sweden: a real-world data study.
Support Care Cancer
; 30(6): 5125-5135, 2022 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-35235039
3.
Correction to: REMIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (polaBR), CART therapies, and lenalidomide/rituximab (R2) based on realworld data in patients with relapsed/refractory diffuse large Bcell lymphoma.
Ann Hematol
; 102(9): 2643-2644, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37432417
4.
Treatment Patterns and Clinical Outcomes of Patients with Moderate to Severe Acute Graft-Versus-Host Disease: A Multicenter Chart Review Study.
Hematol Rep
; 16(2): 283-294, 2024 May 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-38804281
5.
Ponatinib vs. Imatinib as Frontline Treatment for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Matching Adjusted Indirect Comparison.
Adv Ther
; 40(7): 3087-3103, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37208556
6.
Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics.
Proc Natl Acad Sci U S A
; 106(33): 13980-5, 2009 Aug 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-19666590
7.
Tafasitamab Plus Lenalidomide Versus 3 Rituximab-Based Treatments for Non-Transplant Eligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Matching-Adjusted Indirect Comparison.
Adv Ther
; 39(6): 2668-2687, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35403948
8.
A within-trial cost-effectiveness analysis of panitumumab compared with bevacizumab in the first-line treatment of patients with wild-type RAS metastatic colorectal cancer in the US.
J Med Econ
; 21(11): 1075-1083, 2018 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-30091652
9.
A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America.
J Med Econ
; 21(5): 525-536, 2018 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-29480139
10.
Relationship between the Uncompensated Price Elasticity and the Income Elasticity of Demand under Conditions of Additive Preferences.
PLoS One
; 11(3): e0151390, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-26999511
11.
Correction: Relationship between the Uncompensated Price Elasticity and the Income Elasticity of Demand under Conditions of Additive Preferences.
PLoS One
; 11(4): e0154487, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27101104
12.
Selection and quantification of infection endpoints for trials of vaccines against intestinal helminths.
Vaccine
; 29(20): 3686-94, 2011 May 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-21435404
13.
Effect of heterogeneous mixing and vaccination on the dynamics of anthelmintic resistance: a nested model.
PLoS One
; 5(5): e10686, 2010 May 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-20502690
14.
Selection and quantification of infection endpoints for trials of vaccines against intestinal helminths
Artículo
en Inglés
| ARCA | ID: arc-8065
15.
A model using household income and household consumption data to estimate the cost and the effectiveness of subsidies: a modelling study using cross-sectional survey data
Lancet
; 381(suppl.2): S128-S128, 2013.
Artículo
en Inglés
| BVSCARGA, FIOCRUZ | ID: car-1127
Resultados
1 -
15
de 15
1
Próxima >
>>